Abstract
Lung cancer is one of the main causes of death worldwide. Published data show the use of interferons (IFNs) in treating lung tumours. IFNs also have potential for their antiproliferative, antiangiogenic, immunoregulatory and proapoptotic effects. IFN-γ functions as an anticancer agent against various forms of cancer. This study aimed to investigate the effect of IFN-γ liposome (nano) on peripheral lymphocytes from 20 individuals in each group: lung cancer patients compared to healthy individuals. The effectiveness of IFN-γ liposome against oxidative stress was also evaluated in this study. A concentration of 100 U·mL−1 of IFN-γ liposome was used to treat the lymphocytes in the Comet and micronucleus assays based on the preliminary test for the optimal dose. The lymphocytes from lung cancer patients presented with higher DNA damage levels than those of healthy individuals. In healthy individuals, IFN-γ liposome did not cause any DNA damage in the lymphocytes. Also, it caused a significant reduction in DNA damage in the lymphocytes from lung cancer patients in both the Comet and micronucleus assays. The 100 U·mL−1 of IFN-γ liposome significantly reduced the oxidative stress caused by H2O2 and appeared to be effective in both groups using the Comet and micronucleus assays. Results from both Comet and micronucleus assays were consistent. The data obtained indicated that IFN-γ in both forms (IFN-γ bulk and IFN-γ nanoliposome) may potentially be effective for the treatment of lung cancer and showed the ability of IFN-γ liposome to reduce DNA damage more than the bulk form.
Abstract
A research article on the effect of bulk and nanoliposome interferon-γ on lymphocytes from patients with lung cancer compared to healthy controls: assessing the ability of IFN-γ liposome to reduce DNA damage more than the bulk form https://bit.ly/3wvfSyY
Footnotes
This article has been revised according to the author correction published in ERJ Open Res 2021; 7: 50555-2020 [https://doi.org/10.1183/23120541.50555-2020].
Conflict of interest: M. Alhawmdeh has nothing to disclose.
Conflict of interest: M. Isreb has nothing to disclose.
Conflict of interest: A. Aziz has nothing to disclose.
Conflict of interest: B.K. Jacob has nothing to disclose.
Conflict of interest: D. Anderson has nothing to disclose.
Conflict of interest: M. Najafzadeh has nothing to disclose.
Support Statement: The sponsorship by the Mutah University of a PhD studentship to Maysa Alhawamdeh is gratefully acknowledged. The sponsor played no part in the conduct of the work or the writing of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received August 5, 2020.
- Accepted March 23, 2021.
- Copyright ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org